IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Aptuit and Aegerion sign API supply agreement

12:25 AM MST | January 9, 2013 | Deepti Ramesh

Aptuit (Greenwich, CT) says it has signed a long-term supply agreement with Aegerion Pharmaceuticals (Cambridge, MA), for commercial quantities of the active pharmaceutical ingredient (API) lomitapide. Lomitapide is Aegerion’s orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received new drug application (NDA) approval in December of 2012 and is expected to be launched commercially this month. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa